SAN DIEGO--(BUSINESS WIRE)--Oct. 29, 2018--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that Todd S.
Young, Executive Vice President and Chief Financial Officer, will be
leaving the organization effective October 31, 2018 to join another
healthcare company. Elena Ridloff, CFA, Senior Vice President, Investor
Relations will serve as the Company’s Interim Chief Financial Officer.
“On behalf of the entire management team, I want to thank Todd for his
many contributions to the Company and the finance function during an
important period in ACADIA’s growth and wish him all the best in his
future endeavors,” said Steve Davis, ACADIA’s President and Chief
Executive Officer. “Looking ahead, our top priority remains advancing
NUPLAZID as the standard of care for hallucinations and delusions
associated with Parkinson’s disease psychosis and progressing our
late-stage clinical programs focused on innovative medicines to address
unmet medical needs in central nervous system disorders.”
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development and
commercialization of innovative medicines to address unmet medical needs
in central nervous system disorders. ACADIA has developed and is
commercializing the first and only medicine approved for the treatment
of hallucinations and delusions associated with Parkinson’s disease
psychosis. In addition, ACADIA has ongoing clinical development efforts
in additional areas with significant unmet need, including
dementia-related psychosis, schizophrenia inadequate response,
schizophrenia-negative symptoms, major depressive disorder and Rett
syndrome. This press release and further information about ACADIA can be
found at: www.acadia-pharm.com.
About NUPLAZID® (pimavanserin)
NUPLAZID is the first FDA-approved treatment for hallucinations and
delusions associated with Parkinson’s disease psychosis. NUPLAZID is a
non-dopaminergic, selective serotonin inverse agonist preferentially
targeting 5-HT2A receptors that are thought to play an
important role in Parkinson’s disease psychosis. NUPLAZID is an oral
medicine taken once a day with a recommended dose of 34 mg. ACADIA
discovered and developed this new chemical entity and holds worldwide
rights to develop and commercialize NUPLAZID.
Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements include but are
not limited to statements regarding the timing of future events. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties. Actual
events or results may differ materially from those projected in any of
such statements due to various factors, including the uncertainty of
future commercial sales and related items that would impact net sales
during 2018, the risks and uncertainties inherent in drug discovery,
development, approval and commercialization, and the fact that past
results of clinical trials may not be indicative of future trial
results. For a discussion of these and other factors, please refer to
ACADIA’s annual report on Form 10-K for the year ended December 31, 2017
as well as ACADIA’s subsequent filings with the Securities and Exchange
Commission. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. This
caution is made under the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. All forward-looking statements
are qualified in their entirety by this cautionary statement and ACADIA
undertakes no obligation to revise or update this press release to
reflect events or circumstances after the date hereof, except as
required by law.
Important Safety Information and Indication for
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH
Elderly patients with dementia-related psychosis treated with
antipsychotic drugs are at an increased risk of death. NUPLAZID is not
approved for the treatment of patients with dementia-related psychosis
unrelated to the hallucinations and delusions associated with
Parkinson’s disease psychosis.
NUPLAZID is an atypical antipsychotic indicated for the treatment of
hallucinations and delusions associated with Parkinson’s disease
Contraindication: NUPLAZID is contraindicated in patients with a history
of a hypersensitivity reaction to pimavanserin or any of its components.
Rash, urticaria, and reactions consistent with angioedema (e.g., tongue
swelling, circumoral edema, throat tightness, and dyspnea) have been
QT Interval Prolongation: NUPLAZID prolongs the QT interval. The use of
NUPLAZID should be avoided in patients with known QT prolongation or in
combination with other drugs known to prolong QT interval including
Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain
antipsychotic medications, and certain antibiotics. NUPLAZID should also
be avoided in patients with a history of cardiac arrhythmias, as well as
other circumstances that may increase the risk of the occurrence of
torsade de pointes and/or sudden death, including symptomatic
bradycardia, hypokalemia or hypomagnesemia, and presence of congenital
prolongation of the QT interval.
Adverse Reactions: The most common adverse reactions (≥2% for NUPLAZID
and greater than placebo) were peripheral edema (7% vs 2%), nausea (7%
vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%),
constipation (4% vs 3%), and gait disturbance (2% vs <1%).
Drug Interactions: Coadministration with strong CYP3A4 inhibitors (e.g.,
ketoconazole) increases NUPLAZID exposure. Reduce NUPLAZID dose to 10 mg
taken orally as one tablet once daily. Coadministration with strong
CYP3A4 inducers may reduce NUPLAZID exposure. Monitor patients for
reduced efficacy and an increase in NUPLAZID dosage may be needed.
Pediatric Use: Safety and efficacy have not been established in
Dosage and Administration: Recommended dose: 34 mg taken orally once
daily, without titration.
NUPLAZID is available as 34 mg capsules, 17 mg tablets and 10 mg tablets.
For additional Important Safety Information, including Boxed WARNING,
please see the full Prescribing Information for NUPLAZID at https://www.nuplazid.com/pdf/NUPLAZID_Prescribing_Information.pdf.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181029005776/en/
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.